| scholarly article | Q13442814 |
| P50 | author | Xinyang Li | Q89706213 |
| P2093 | author name string | Shuang Yang | |
| Xiuqing Zhang | |||
| Bo Li | |||
| Xiaoyan Gao | |||
| Xinhua Zhang | |||
| Lin Jiang | |||
| Yong Hou | |||
| Naibo Yang | |||
| Yingying Ma | |||
| Mi Huang | |||
| Haitao Xiang | |||
| Xiaopan Liu | |||
| Chuxin Liu | |||
| Meiniang Wang | |||
| P2860 | cites work | PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety | Q91400753 |
| The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation | Q24293346 | ||
| Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice | Q24311328 | ||
| Mutations in PCSK9 cause autosomal dominant hypercholesterolemia | Q28202519 | ||
| Selection and identification of single domain antibody fragments from camel heavy-chain antibodies | Q28250517 | ||
| Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials | Q29617910 | ||
| Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae | Q30843840 | ||
| Overexpression of low density lipoprotein (LDL) receptor eliminates LDL from plasma in transgenic mice | Q34175241 | ||
| Bacterial cytoplasm as an effective cell compartment for producing functional VHH-based affinity reagents and Camelidae IgG-like recombinant antibodies | Q34234412 | ||
| Generation of single domain antibody fragments derived from camelids and generation of manifold constructs | Q34386048 | ||
| Off-rate screening for selection of high-affinity anti-drug antibodies | Q34887838 | ||
| Comparative Analysis of Immune Repertoires between Bactrian Camel's Conventional and Heavy-Chain Antibodies | Q36121467 | ||
| Progression of vascular calcification is increased with statin use in the Veterans Affairs Diabetes Trial (VADT). | Q36334643 | ||
| Prokaryotic expression of antibodies | Q36366522 | ||
| Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels | Q36481769 | ||
| Plasma PCSK9 levels are significantly modified by statins and fibrates in humans | Q36728777 | ||
| Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a | Q37360326 | ||
| Therapeutic antibodies: successes, limitations and hopes for the future | Q37491236 | ||
| Pichia pastoris: a recombinant microfactory for antibodies and human membrane proteins. | Q38104572 | ||
| Half-life extended biotherapeutics | Q38770067 | ||
| Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura | Q38818496 | ||
| Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation | Q38855416 | ||
| Statins and Their Effect on PCSK9-Impact and Clinical Relevance | Q38868416 | ||
| Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies | Q39557682 | ||
| PCSK9 inhibitors may improve cardiovascular outcomes-Can we afford them? | Q39623145 | ||
| Increased half-life and enhanced potency of Fc-modified human PCSK9 monoclonal antibodies in primates. | Q41443645 | ||
| Proprotein convertase subtilisin/Kexin type 9 (PCSK9) single domain antibodies are potent inhibitors of low density lipoprotein receptor degradation | Q41834894 | ||
| Expression of single-chain variable fragments fused with the Fc-region of rabbit IgG in Leishmania tarentolae | Q41931233 | ||
| Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. | Q44442238 | ||
| A comparison of strategies to stabilize immunoglobulin Fv-fragments | Q46093365 | ||
| Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists. | Q46857204 | ||
| Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis | Q49082819 | ||
| Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development. | Q54204604 | ||
| A single domain antibody against the Cys- and His-rich domain of PCSK9 and evolocumab exhibit different inhibition mechanisms in humanized PCSK9 mice | Q58454981 | ||
| From Screening to Targeted Degradation: Strategies for the Discovery and Optimization of Small Molecule Ligands for PCSK9 | Q90949040 | ||
| Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias | Q91301940 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 16 | |
| P577 | publication date | 2020-02-13 | |
| P1433 | published in | Clinical and translational medicine | Q27724586 |
| P1476 | title | The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats | |
| P478 | volume | 9 |
| Q99636619 | Exploring cellular biochemistry with nanobodies | cites work | P2860 |
Search more.